查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1512044

美国大麻市场规模、份额和趋势分析报告：2024-2030 年按来源、衍生物、最终用途和细分市场进行的预测

U.S. Cannabis Market Size, Share & Trends Analysis Report By Source (Hemp, Marijuana), By Derivatives (CBD, THC), By End-use (Medical Use, Recreational Use), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国大麻市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，美国大麻市场规模预计将达到401亿美元，2024年至2030年的复合年增长率为13.7%。药用大麻合法化、消费者可支配收入增加、製药行业对大麻的需求增加、消费者对大麻健康益处的认识提高、大型製造商的存在以及美国农业法案的核准等因素预计将提振市场成长。

大麻通常用于治疗多种疾病，包括癌症、精神障碍、疼痛管理和噁心以及娱乐。癌症高发生率预计将成为预测期内推动医用大麻采用的因素之一。例如，美国癌症协会2023年1月发表的报导估计，美国将有609,820人死于癌症，并且将有1,958,310个新病例被诊断出患有癌症。此外，两种大麻二酚（CBD）药物大麻隆和屈大麻酚已在美国获得FDA核准用于治疗化疗引起的噁心和呕吐。

此外，大众对大麻治疗功效的认识不断提高，以及透过合作伙伴关係推出大麻认证计划，正在推动市场成长。例如，2023年12月，贝拉明大学推出了肯塔基州公立大学提供的大麻教育认证计划，重点是快速变化的大麻产业中的农业、商业、医学和法律。

随着美国各地医用和娱乐大麻合法化，许多名人和主流公司都希望从这一趋势中获利。例如，Jay-Z 和 Snoop Dogg 等名人也加入了这项运动，推出了品牌大麻产品（字母组合）。但狂热的大麻消费者希望了解名人参与种植过程的程度。儘管有这样的审查，我们仍然可以预期更多的名人会追随这一趋势并进入大麻种植行业。

此外，大麻种植的新技术和改进也在不断开发。随着对技术先进的大麻生产的需求不断增加，这些增强的技术预计将帮助种植者优化资源，进一步推动市场成长。

美国大麻市场报告亮点

  • 从来源来看，大麻产业在 2023 年的销售中占据了最大份额，因为用于医疗目的的大麻正在获得认可并且其使用正在合法化。
  • 从衍生性商品来看，由于人们对含有 CBD 的食品、化妆品和药品的接受度不断提高，需求不断增加，CBD 细分市场将占据最大的收益占有率，并在 2023 年主导市场。
  • 按最终用途划分，由于支持 CBD 在治疗各种慢性疾病方面的效用的研究活动和临床试验的增加，医疗用途领域在 2023 年占据了最大的收益占有率。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章美国大麻市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 案例研究分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
  • 监管状况

第 4 章 2018-2030 年美国大麻市场細項分析（按来源）

  • 定义和范围
  • 源细分仪表板
  • 2018-2030年市场规模、预测及趋势分析
  • 麻
    • 2018 年至 2030 年市场估计与预测
    • 油
    • 工业大麻
  • 大麻
    • 花
    • 油和酊剂

第五章美国大麻市场細項分析（依衍生物），2018-2030

  • 定义和范围
  • 衍生物细分仪表板
  • 2018-2030年市场规模、预测及趋势分析
  • CBD
    • 2018 年至 2030 年市场估计与预测
  • THC
    • 2018 年至 2030 年市场估计与预测
  • 其他的
    • 2018 年至 2030 年市场估计与预测

第六章 2018-2030 年美国大麻市场細項分析（依最终用途）

  • 定义和范围
  • 最终用途细分仪表板
  • 2018-2030年市场规模、预测及趋势分析
  • 工业用途
    • 2018 年至 2030 年市场估计与预测
  • 医疗用途
    • 2018 年至 2030 年市场估计与预测
    • 慢性疼痛
    • 忧郁症和焦虑
    • 关节炎
    • 创伤后压力症候群（PTSD）
    • 癌症
    • 偏头痛
    • 癫痫
    • 阿兹海默症
    • 多发性硬化症
    • 肌萎缩侧索硬化症
    • 妥瑞症
    • 糖尿病
    • 帕金森氏症
    • 青光眼
    • 其他的
  • 休閒用途
    • 2018 年至 2030 年市场估计与预测

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 公司市场分析
  • 公司简介
    • Tilray Brands
    • Canopy Growth Corporation
    • Medical Marijuana, Inc.
    • NuLeaf Naturals, LLC
    • CV Sciences, Inc.
    • CHARLOTTE'S WEB.
    • The Cronos Group
    • Organigram Holding, Inc
    • Irwin Naturals
    • Aurora Cannabis
Product Code: GVR-2-68038-978-4

U.S. Cannabis Market Growth & Trends:

The U.S. cannabis market size is expected to reach USD 40.10 billion by 2030, registering a CAGR of 13.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as legalization of medicinal cannabis, growing consumer disposable income, rising demand for cannabis from the pharmaceutical industry, growing consumer awareness of the health benefits of cannabis, presence of major manufacturers, and the approval of the U.S. farm bill are expected to boost the market growth.

Cannabis is generally used for the treatment of various conditions, such as cancer, mental disorders, pain management, & nausea, and for recreational purposes. The high prevalence of cancer is expected to be one of the factors driving the adoption of medical marijuana over the forecast period. For instance, according to an article published by the American Cancer Society in January 2023, 609,820 cancer deaths and 1,958,310 new cancer cases were anticipated to occur in the U.S. In addition to that, two cannabidiol (CBD) drugs namely nabilone and dronabinol are approved by the FDA for the treatment of vomiting and nausea caused by chemotherapy in the U.S.

Furthermore, rising awareness among people regarding the therapeutic benefits of cannabis and the launch of cannabis certification programs through partnerships drives market growth. For instance, in December 2023, Bellarmine University introduced a cannabis education certificate program offered by a public Kentucky University focusing on agriculture, business, medicine, and law in the fast-changing cannabis industry.

With the legalization of cannabis in different areas of the U.S. for medical & recreational use, many well-known personalities and mainstream companies are seeking to benefit from this trend. For instance, celebrities such as Jay-Z and Snoop Dogg have joined this movement by launching branded cannabis products (Monogram). However, avid cannabis consumers seek information regarding the extent of the celebrity's involvement in the cultivation process. Despite this scrutiny, more celebrities are expected to follow this trend and enter the cannabis cultivation industry.

Moreover, new technologies and improvements are continually being developed for the cultivation of cannabis. With an increasing demand for technologically advanced cannabis production, these expanded techniques are anticipated to assist cultivators in optimizing their resources, which further drives the market growth.

U.S. Cannabis Market Report Highlights:

  • Based on source, the marijuana segment accounted for the largest revenue share in 2023 due to the recognition of cannabis for medical purposes and the increasing legalization of its use
  • Based on derivative, the CBD segment dominated the market with the largest revenue share in 2023, owing to growing acceptance and a rise in demand for CBD-infused food, cosmetics, and medication
  • Based on end-use, the medical use segment held the largest revenue share in 2023 due to the increasing research activity and growing clinical trials supporting its benefits in treating various chronic diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Source
    • 1.2.2. Derivatives
    • 1.2.3. End-use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
    • 2.2.1. Source outlook
    • 2.2.2. Derivatives outlook
    • 2.2.3. End-use outlook
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Cannabis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing adoption of medical marijuana for treatment of chronic diseases
      • 3.2.1.2. Impending legalization of marijuana for recreational/adult use
      • 3.2.1.3. Rising number of research studies on cannabis for various ailments
      • 3.2.1.4. Growing legalization and awareness of cannabis in various states in the U.S.
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of cannabis and CBD-based products
      • 3.2.2.2. lack of consistency in advertising policies regarding cannabis
    • 3.2.3. Case Study Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Regulatory Landscape

Chapter 4. U.S. Cannabis Market Segment Analysis, By Source, 2018 - 2030 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Source Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4. Hemp
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Hemp oil
      • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Industrial Hemp
      • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Marijuana
      • 4.5.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.2. Flower
      • 4.5.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.3. Oil and Tinctures
      • 4.5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Cannabis Market Segment Analysis, By Derivative, 2018 - 2030 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. Derivatives Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4. CBD
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. THC
    • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Cannabis Market Segment Analysis, By End-use, 2018 - 2030 (USD Million)

  • 6.1. Definition and Scope
  • 6.2. End-use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4. Industrial Use
    • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Medical Use
    • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.2. Chronic Pain
      • 6.5.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.3. Depression and Anxiety
      • 6.5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.4. Arthritis
      • 6.5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.5. Post Traumatic Stress Disorder (PTSD)
      • 6.5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.6. Cancer
      • 6.5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.7. Migraines
      • 6.5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.8. Epilepsy
      • 6.5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.9. Alzheimer's Disease
      • 6.5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.10. Multiple Sclerosis
      • 6.5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.11. Amyotrophic Lateral Sclerosis
      • 6.5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.12. Tourette's Syndrome
      • 6.5.12.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.13. Diabetes
      • 6.5.13.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.14. Parkinson's Disease
      • 6.5.14.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.15. Glaucoma
      • 6.5.15.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.16. Others
      • 6.5.16.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Recreational Use
    • 6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Market Position Analysis
  • 7.4. Company Profiles
    • 7.4.1. Tilray Brands
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Service Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Canopy Growth Corporation
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Service Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Medical Marijuana, Inc.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Service Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. NuLeaf Naturals, LLC
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Service Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. CV Sciences, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Service Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. CHARLOTTE'S WEB.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Service Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. The Cronos Group
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Service Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Organigram Holding, Inc
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Service Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Irwin Naturals
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Service Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Aurora Cannabis
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Service Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. cannabis market, by source, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis market, by derivatives, 2018 - 2030 (USD Million)
  • Table 5 U.S. cannabis market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Value-chain-based sizing & forecasting
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market research approaches
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. cannabis market: market outlook
  • Fig. 9 U.S. cannabis competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook.
  • Fig. 12 Industry value chain analysis
  • Fig. 13 U.S. cannabis market driver impact
  • Fig. 14 U.S. cannabis market restraint impact
  • Fig. 15 U.S. cannabis market strategic initiatives analysis
  • Fig. 16 U.S. cannabis market: Source movement analysis
  • Fig. 17 U.S. cannabis market: Source outlook and key takeaways
  • Fig. 18 Hemp market estimates and forecasts, 2018 - 2030
  • Fig. 19 Hemp Oil market estimates and forecasts, 2018 - 2030
  • Fig. 20 Industrial Hemp market estimates and forecasts, 2018 - 2030
  • Fig. 21 Marijuana market estimates and forecasts, 2018 - 2030
  • Fig. 22 Flower market estimates and forecasts, 2018 - 2030
  • Fig. 23 Oil and Tinctures market estimates and forecasts, 2018 - 2030
  • Fig. 24 U.S. cannabis market: Derivatives movement analysis
  • Fig. 25 U.S. cannabis market: Derivatives outlook and key takeaways
  • Fig. 26 CBD market estimates and forecasts, 2018 - 2030
  • Fig. 27 THC market estimates and forecasts, 2018 - 2030
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030
  • Fig. 29 U.S. cannabis market: End-use movement analysis
  • Fig. 30 U.S. cannabis market: End-use outlook and key takeaways
  • Fig. 31 Industrial Use market estimates and forecasts, 2018 - 2030
  • Fig. 32 Medical Use market estimates and forecasts, 2018 - 2030
  • Fig. 33 Chronic Pain market estimates and forecasts, 2018 - 2030
  • Fig. 34 Depression and Anxiety market estimates and forecasts, 2018 - 2030
  • Fig. 35 Arthritis market estimates and forecasts, 2018 - 2030
  • Fig. 36 Post Traumatic Stress Disorder (PTSD) market estimates and forecasts, 2018 - 2030
  • Fig. 37 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 38 Migraines market estimates and forecasts, 2018 - 2030
  • Fig. 39 Epilepsy market estimates and forecasts, 2018 - 2030
  • Fig. 40 Alzheimer's market estimates and forecasts, 2018 - 2030
  • Fig. 41 Multiple Sclerosis market estimates and forecasts, 2018 - 2030
  • Fig. 42 AIDS market estimates and forecasts, 2018 - 2030
  • Fig. 43 Amyotrophic Lateral Sclerosis market estimates and forecasts, 2018 - 2030
  • Fig. 44 Tourette's market estimates and forecasts, 2018 - 2030
  • Fig. 45 Diabetes market estimates and forecasts, 2018 - 2030
  • Fig. 46 Parkinson's market estimates and forecasts, 2018 - 2030
  • Fig. 47 Glaucoma market estimates and forecasts, 2018 - 2030
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030
  • Fig. 49 Recreational Use market estimates and forecasts, 2018 - 2030
  • Fig. 50 Key company categorization